FAQ  /  Women's Hormone Health

Is Testosterone for Women Only About Libido?

I use testosterone therapy for selected women in clinical practice. The goal here is the same standard as the rest of this site: say what the evidence supports, say where uncertainty remains, and do not pretend the science is more finished than it is.

This page is educational. It is not a recommendation to start testosterone, and it is not a dosing guide. Whether therapy is right for you belongs in a visit with history, exam, appropriate labs, and shared decision-making.

For the full evidence-graded guide, start here: Testosterone in Women (research).

Sexual Function: The Randomized Evidence Is Real

---

Sexual function (desire, satisfying sexual events, arousal, pleasure, and distress related to low desire) is where the trial data are strongest for postmenopausal women.

Islam and colleagues published a 2019 systematic review and meta-analysis in The Lancet Diabetes & Endocrinology that pooled 36 randomized controlled trials including 8,480 women. Testosterone improved satisfying sexual events, sexual desire, arousal, and pleasure, and reduced sexual distress compared with placebo or comparator. Acne and hirsutism also increased, which is expected androgen biology and part of informed consent, not a reason to dismiss the benefit data.

The 2019 Global Consensus Position Statement on testosterone therapy for women (Davis and colleagues, Journal of Clinical Endocrinology & Metabolism) concludes that hypoactive sexual desire disorder (HSDD) is the indication with sufficient evidence to support treatment in postmenopausal women. That is the clearest guideline-level statement available today.

So when people say “testosterone for women is just about libido,” they have the emphasis backward. Libido and related sexual symptoms are not a side curiosity. They are the best-proven reason we have to treat. They are also not the only reason women feel better on therapy, which is the rest of this page.

Related: GSM and vaginal dryness · Is hormone optimization right for me?

Energy, Mood, and Cognition: Common in Practice, Still Being Built in Trials

---

In clinic, women frequently describe more energy, steadier mood, and clearer thinking after testosterone is added, often on top of estrogen they are already taking. That pattern shows up in careful observational work as well.

Hernandez and colleagues (Journal of Sexual Medicine, 2026) followed 279 women who had testosterone added to established hormone therapy. Six of eight symptom clusters improved, covering 15 of 24 individual symptoms. Among the larger absolute improvements: vaginal dryness 59%, hot flashes 54.9%, and libido 54.8%. Every woman in that cohort was already on estrogen, so these changes are about adding testosterone, not about starting hormones from zero.

Two clusters did not improve: neuropathic and cardiopulmonary symptoms. Reporting the misses matters. Testosterone is not a universal symptom solvent.

How should you read this next to the Global Consensus? The Consensus found insufficient evidence for cognition and did not demonstrate a benefit for general wellbeing or depressed mood in the pooled randomized data available in 2019. That is not the same sentence as “testosterone does nothing for energy or mood.” Most trials were small, short, often already included estrogen, and were rarely powered for energy, mood, or cognition as primary endpoints. Absence of definitive RCT proof is not evidence of absence. Hernandez is the kind of real-world signal that keeps those domains in an honest clinical conversation while we wait for better trials.

Weaker survey-only telehealth papers (for example Elggren et al., 2026) sit below Hernandez if they are mentioned at all.

Bone, Muscle, and Body Composition: Last on Purpose

---

Androgen receptors in bone and muscle make these domains biologically interesting. Women care about them for good reason. They come last on this page because the major evidence syntheses have not established them as proven treatment effects yet.

The 2019 Global Consensus concluded that available data do not support an effect of testosterone on bone mineral density at the spine, hip, or femoral neck. For lean body mass, total body fat, and muscle strength, pooled randomized analyses showed no statistically significant effect. Islam’s meta-analysis likewise does not establish bone or body-composition benefit as a demonstrated reason to prescribe.

Important nuance: many of those trials were not designed or powered to settle bone density, lean mass, or strength. Short duration and concurrent estrogen make “no significant effect detected” a weaker claim than a large, long, purpose-built negative trial. The honest clinical stance is: these outcomes remain incompletely tested, not that biology was disproven. Until stronger trials exist, I do not promise denser bones or a new physique from testosterone alone. Resistance training, protein intake, sleep, and therapies actually studied for bone stay the foundation. Testosterone is not a stand-alone osteoporosis drug.

How Testosterone Levels Change in Women

---

Circulating testosterone in women tends to decline gradually from early adulthood, driven in large part by falling adrenal androgen precursors (including DHEA pathways) over decades. Natural menopause is mainly an estradiol story; it is not an abrupt testosterone cliff. Bilateral oophorectomy can remove ovarian androgen contribution more suddenly. Midlife symptoms deserve a full differential, not a single hormone slogan. For the transition years when estradiol becomes unstable and progesterone falls earlier, see also What is perimenopause?

Labs: Clinical Diagnosis First; Levels for Safety and Monitoring

---

There is no validated testosterone cutoff that diagnoses “you need testosterone” the way a glucose threshold diagnoses diabetes. The Global Consensus is clear: low sexual desire / HSDD is diagnosed clinically. Testosterone concentrations help exclude an elevated baseline before treatment and help confirm that therapy stays in a safe treatment range. They do not make the diagnosis by themselves.

A result inside a wide “normal” reference interval also does not prove you are optimized. Those intervals are built mainly to flag disease in populations. Symptoms, exam, differential diagnosis, and shared goals come first. Labs keep treatment honest and safe.

If thinning hair is a concern after starting therapy, see Is my hair thinning because of my testosterone dose? and the related hair loss and DHT blog post.

Monitoring and Safety

---

Supervised testosterone therapy includes a plan, not a one-time prescription. Before starting, baseline assessment excludes women who should not start and documents symptoms you care about. After initiation, levels and clinical response are typically rechecked in about 4 to 12 weeks, then periodically while on therapy. The intent is approximate premenopausal physiologic exposure, individualized, not male-range dosing and not social-media escalation.

Watch for androgenic effects: acne, increased facial or body hair, scalp thinning in susceptible women, oily skin, voice deepening, and clitoral enlargement. Voice change and clitoromegaly can be irreversible. That is why more is not better, and why dose is adjusted to response rather than chased upward for a larger libido effect. Overshoot signs (new or progressive virilization, levels above the intended treatment range, or other adverse effects) are a reason to reduce or stop and reassess.

Pregnancy and breastfeeding are absolute exclusions. Unexplained bleeding, significant liver disease, or uncontrolled cardiovascular risk need evaluation first. If you have active or prior hormone-sensitive cancer, hormone decisions belong with oncology-aligned specialty care. Do not start or change therapy on your own.

This monitoring description is route-neutral. How your clinician delivers therapy is an individualized decision; this FAQ does not rank pellets, injections, creams, or other routes.

Testosterone and Breast Cancer

---

No study has demonstrated that testosterone therapy increases breast cancer risk in women. That is the clearest public statement the evidence allows today. The randomized trials we have are still generally underpowered and too short to settle lifelong cancer outcomes with finality, so honesty about study limits stays part of the conversation. It does not overturn the no-increased-risk finding.

The biology and clinical literature lean in a reassuring direction for many readers who have been told otherwise. Hickey and colleagues (Nature Medicine, 2021) describe the androgen receptor as a tumor suppressor in estrogen-receptor-positive breast cancer. Observational series from Glaser and colleagues (Maturitas, 2013; BMC Cancer, 2019) reported invasive breast cancer incidence at or below expected rates in women treated with subcutaneous testosterone implant regimens, including protocols that combine testosterone with anastrozole. Donovitz and Cotten (European Journal of Breast Health, 2021) similarly reported breast cancer incidence below SEER expectations in women treated with testosterone or testosterone/estradiol pellets.

This FAQ is education about risk framing, not a breast cancer treatment guide. If you have active or prior breast cancer, decisions about hormones belong with oncology-aligned specialty care coordinated with your clinicians. Bring the question to that team rather than starting or stopping therapy on your own.

Off-Label Status (United States) and Why the Wording Is Careful

---

In the United States there is no FDA-approved testosterone product for women for any indication. When U.S. clinicians prescribe testosterone for postmenopausal women with HSDD or related goals, use is off-label. Australia, by contrast, has an approved female testosterone product (AndroFeme 1). Off-label does not mean reckless or imaginary. It does mean informed consent, documentation, compounding or product selection under clinical judgment, and monitoring all matter.

In September 2026 the FDA held a public workshop on testosterone therapy for menopausal women and discussed energy, mood, bone, muscle, and cognition as reasons women seek therapy, while noting that guidelines do not treat those uses as established indications. That is exactly why this page leads with sexual-function RCTs, then grades everything else honestly.

Myths and Misunderstandings

---

• “Testosterone for women is only a libido drug.” Incomplete. Sexual function is the best-supported benefit, and that is a feature of the evidence, not a limitation of the hormone. Other domains are commonly improved in practice and are still being clarified in trials.
• “If my sex drive is fine, testosterone is irrelevant.” Not necessarily. In the Hernandez cohort, baseline fatigue (92.9%) was even more common than low libido (89.6%). Women seek care for energy and related symptoms at least as often as for desire alone. That does not turn every fatigue complaint into an automatic prescription; it does mean sexual desire is a poor sole screen.
• “Guidelines that urge caution are just old-fashioned myths.” No. Guideline caution about bone, muscle, cognition, and mood reflects what pooled RCTs have demonstrated so far, and how underpowered many of those endpoints were. Caution and therapeutic use can coexist when the conversation is graded.
• “A normal lab means nothing is wrong” or “a low-ish lab means I need testosterone.” Both oversimplify. Diagnosis is clinical. Labs exclude high baselines and guide safe dosing.

Bottom Line

---

Testosterone for women is not only about libido. Sexual function is where randomized trials give us the firmest footing (Islam 2019; Global Consensus 2019). Energy, mood, and related symptoms often improve when testosterone is added in real-world cohorts such as Hernandez 2026, including for women whose biggest complaint is not desire. Bone and body composition remain biologically plausible and incompletely tested; I will not overclaim them. Breast cancer risk has not been shown to rise on therapy, and observational implant series are carefully reassuring on incidence; active or prior breast cancer decisions still belong with oncology-aligned specialty care.

The right clinic question is practical: Do your symptoms and goals fit a trial-supported use or a carefully consented off-label discussion, have we looked for other drivers, and can we treat and monitor responsibly? If you want the deeper evidence map, read Testosterone in Women.

— Dr. Darrell Wilcox · @wellnessdoc_4everyoung on Instagram

This content is for educational purposes only and does not constitute medical advice. It is not a substitute for professional medical evaluation, diagnosis, or treatment. It is not a recommendation to start testosterone and is not a dosing guide. Always consult a qualified healthcare provider regarding your specific history, symptoms, labs, and contraindications. Dr. Wilcox is licensed to practice in multiple states. See About for current licensure.